Center for Primary Health Care Research, Department of Clinical Sciences, Lund University/Region Skåne, Malmö, Sweden.
Departments of Family Medicine and Community Health and of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Cancer Causes Control. 2022 Feb;33(2):213-222. doi: 10.1007/s10552-021-01513-2. Epub 2021 Nov 7.
Prostate cancer is the second most common cancer in men and a leading cause of cancer mortality worldwide. Men with drug use disorders (DUD) may potentially be at high risk for prostate cancer mortality because of delayed diagnosis and/or undertreatment. In this study, we aimed to investigate prostate cancer incidence, mortality, and stage at time of diagnosis among men with DUD compared to the general male population in Sweden.
We performed a follow-up study based on Swedish national register data for the period January 1997-December 2016. The study was based on 1,361,532 men aged 50-75 years at inclusion, of whom 9,259 were registered with DUD. Cox regression analysis was used to compute adjusted hazard ratios (HRs) for incident and fatal prostate cancer, and cancer stage at time of diagnosis, associated with DUD.
DUD was associated with a slightly increased risk of incident prostate cancer (HR: 1.07, 95% confidence interval [CI] 1.00-1.14, p = 0.048) and substantially higher risk of fatal prostate cancer (HR: 1.59, 95% CI 1.40-1.82, p < 0.001), adjusted for age, socioeconomic factors, and comorbidities related to tobacco smoking and alcohol use disorder. No association was found between DUD and prostate cancer stage at diagnosis.
Men with DUD have an increased risk of fatal prostate cancer, possibly related to undertreatment in this patient population. Our findings should raise attention among medical staff and decision-makers towards a disadvantaged group of men in need of easily accessible prostate cancer evaluation and treatment.
前列腺癌是男性中第二常见的癌症,也是全球癌症死亡的主要原因。患有药物使用障碍(DUD)的男性由于诊断延迟和/或治疗不足,可能面临更高的前列腺癌死亡率风险。在这项研究中,我们旨在调查与瑞典普通男性人群相比,患有 DUD 的男性的前列腺癌发病率、死亡率和诊断时的分期。
我们基于瑞典全国登记数据进行了一项随访研究,研究时间为 1997 年 1 月至 2016 年 12 月。该研究基于纳入时年龄在 50-75 岁的 1361532 名男性,其中 9259 名患有 DUD。我们使用 Cox 回归分析计算了与 DUD 相关的新发和致命前列腺癌以及诊断时癌症分期的调整后的风险比(HR)。
DUD 与新发前列腺癌的风险略有增加相关(HR:1.07,95%置信区间 [CI] 1.00-1.14,p=0.048),与致命前列腺癌的风险显著增加相关(HR:1.59,95%CI 1.40-1.82,p<0.001),调整了年龄、社会经济因素以及与吸烟和酒精使用障碍相关的共病。DUD 与诊断时前列腺癌的分期之间没有关联。
患有 DUD 的男性患致命前列腺癌的风险增加,这可能与该患者人群的治疗不足有关。我们的研究结果应引起医务人员和决策者对需要易于获得的前列腺癌评估和治疗的这一弱势男性群体的关注。